Detailed Clinical Characteristics of the Patients With No Previous Chemotherapy
| Patient No. . | Sex/Age . | FR . | Prior AIDS . | CD4/μL . | p24/μL . | LDH . | Histology . | Extranodal Site (other than BM) . | Bulky . | BM . | Stage . | PS . | Response . | RT/Response . | Duration (mo) . | Survival (mo) . | Status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/28 | HO | OI | 54 | 169.4 | 1539 | Burkitt | Liver | + | − | IV | 3 | NR | — | — | 6 | D/L |
| 3 | M/49 | HO | KS | 4.3 | 3.5 | 720 | DLBCL | Palatum | + | + | IV | 3 | NE | — | — | — | — |
| 5 | M/32 | IVDU | — | 39 | 0 | 195 | Burkitt | CNS | − | − | IV | 1 | CR | — | 27+ | 28+ | A/W |
| 6 | M/40 | IVDU | — | 14 | 128 | 263 | ALC | Skin | − | + | IV | 1 | PR | — | 6+ | 9+ | D/L |
| 15 | F/29 | HE | — | 69 | 15.5 | 1410 | DLBCL | Stomach | − | + | IV | 2 | CR | — | 10+ | 13+ | D/L |
| 19 | M/39 | HO | KS | 42 | 98 | 258 | L | — | + | − | II | 1 | PR | — | 1+ | 9+ | D/L |
| 24 | F/34 | HE | OI | 10 | 24 | 351 | DLCBL | Stomach | + | − | IV | 2 | NR | — | — | 8+ | D/L |
| 26 | M/37 | HE | — | 167 | 0 | 372 | DLCBL | — | − | + | IV | 0 | CR | — | 7+ | 9+ | A/W |
| Patient No. . | Sex/Age . | FR . | Prior AIDS . | CD4/μL . | p24/μL . | LDH . | Histology . | Extranodal Site (other than BM) . | Bulky . | BM . | Stage . | PS . | Response . | RT/Response . | Duration (mo) . | Survival (mo) . | Status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/28 | HO | OI | 54 | 169.4 | 1539 | Burkitt | Liver | + | − | IV | 3 | NR | — | — | 6 | D/L |
| 3 | M/49 | HO | KS | 4.3 | 3.5 | 720 | DLBCL | Palatum | + | + | IV | 3 | NE | — | — | — | — |
| 5 | M/32 | IVDU | — | 39 | 0 | 195 | Burkitt | CNS | − | − | IV | 1 | CR | — | 27+ | 28+ | A/W |
| 6 | M/40 | IVDU | — | 14 | 128 | 263 | ALC | Skin | − | + | IV | 1 | PR | — | 6+ | 9+ | D/L |
| 15 | F/29 | HE | — | 69 | 15.5 | 1410 | DLBCL | Stomach | − | + | IV | 2 | CR | — | 10+ | 13+ | D/L |
| 19 | M/39 | HO | KS | 42 | 98 | 258 | L | — | + | − | II | 1 | PR | — | 1+ | 9+ | D/L |
| 24 | F/34 | HE | OI | 10 | 24 | 351 | DLCBL | Stomach | + | − | IV | 2 | NR | — | — | 8+ | D/L |
| 26 | M/37 | HE | — | 167 | 0 | 372 | DLCBL | — | − | + | IV | 0 | CR | — | 7+ | 9+ | A/W |
Previous chemotherapy included F-MACHOP (patient no. 1), α-interferon (patient no. 3), CVP (patients no. 5, 6, and 15), Vincristine + prednisone (patient no. 19), ABVD (patient no. 24), and CHOP (patient no. 26).
Abbreviations: HO, homosexual; HE, heterosexual; OI, opportunistic infection; BM, bone marrow; PTCL, peripheral T-cell lymphoma; ALC, anaplastic large-cell lymphoma; U, unclassified lymphoma; L, lymphoblastic lymphoma; ND, not done; NR, no response; NE, not evaluable;D/L, dead with lymphoma; A/W, alive and well; D/WS, dead with wasting syndrome; LFU, lost to follow-up; D/INF, dead with infection.